XJPX
4577
Market cap220mUSD
Jul 10, Last price
1,250.00JPY
1D
0.24%
1Q
-10.84%
Jan 2017
-39.00%
IPO
-3.11%
Name
Daito Pharmaceutical Co Ltd
Chart & Performance
P/E
18.83
P/S
0.71
EPS
66.38
Div Yield, %
3.01%
Shrs. gr., 5y
16.60%
Rev. gr., 5y
2.39%
Revenues
50.64b
+7.99%
Net income
1.91b
-42.08%
CFO
5.90b
+13.80%
Dividend
May 28, 202620 JPY/sh
Earnings
Jul 10, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑05 | 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||